For symptomatic adult asthma patients already using ICS/LABA
SPIRIVA® Respimat® (tiotropium bromide) is indicated as an add-on maintenance bronchodilator treatment in the EU for adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 μg budesonide/day or equivalent) and long-acting β2 agonists and who experienced one or more severe exacerbations in the previous year.1
An additional treatment option in asthma
SPIRIVA® Respimat® redefines what’s possible by offering an additional option to help patients stay in front of asthma.
It is a fact that about 50% of patients remain symptomatic despite the availability of standard maintenance treatment with inhaled corticosteroids (ICS) plus long acting beta agonists (LABA).2 Remaining symptomatic puts patients at greater risk of an asthma exacerbation.3
This video explains how SPIRIVA® Respimat® offers doctors an additional asthma treatment option for the many patients who remain symptomatic despite adhering to ICS plus LABA maintenance therapy.
SPIRIVA®(tiotropium) is delivered by the Respimat® inhaler in a unique mist that can make its way deep into the lungs.4-6
SPIRIVA® Respimat® is known to work in a different way to other asthma drugs: unlike LABAs that stimulate bronchodilation7, SPIRIVA® Respimat® blocks bronchoconstriction.8
SPIRIVA® Respimat® has recently been incorporated into the Global Initiative for Asthma (GINA) treatment recommendations as an alternative add-on therapy at Steps 4 and 5 in adult patients with a history of asthma exacerbations.9
The benefits of SPIRIVA® Respimat® (tiotropium bromide) when added to ICS/LABA have been demonstrated in clinical studies:
- Significantly improved lung function vs control10
- Improved asthma symptoms vs control10
- Significantly reduced risk of severe exacerbation vs control10
The benefits of SPIRIVA® Respimat® have also been demonstrated regardless of the baseline characteristics of patients (eg, allergic status, age, smoking status, BMI).11